Oryzon to attend the 32nd ANNUAL J.P. MORGAN Healthcare Conference in San Francisco
The company will also present its advances in its LSD1 programs at the Biotech-Showcase 2014 parallel meeting Barcelona, December 16th, 2013. Oryzon announced today that its C.E.O. Dr. Buesa will attend the 32nd ANNUAL J.P. MORGAN Healthcare Conference on JANUARY 13–16, 2014 at the Westin St. Francis to discuss with the leaders of the industry the potential of epigenetics in devastating diseases.
The company will also participate at the parallel event Biotech Showcase 2014 where it will present the advances in its Alzheimer’s disease program on Jan 15th 2014 at 9:45:00 on the Track B - Mission I (4th Floor) to be held at the Parc55 Wyndham-Union Square Hotel.
Barcelona, Spain
The J.P. Morgan HealthCare Conference brings together industry leaders, financial sponsors and investors to explore innovation,market and trends in the pharmaceutical industry. Epigenetics is certainly one of the most innovative areas and ORYZON will have, for the second consecutive year, the opportunity to discuss its different programs centered in Lysine specific demethylase 1 (LSD1, KDM1A), an epigenetic modulator able to regulate gene expression by demethylating histones, with industry leaders and investors.